Introduction
Proliferation and differentiation of primitive hematopoietic stem cells in the bone marrow (BM) reservoir is followed by leukocyte release to the circulation. This process is regulated by dynamic interactions between the nervous and immune systems with the stromal microenvironment. 1, 2 Although the majority of stem and progenitor cells reside within the BM, a very small subset of immature cells are also found in the peripheral blood as part of steady-state homeostasis. 3 However, the mechanisms governing progenitor cell egress to the circulation are currently poorly defined. The basal low levels of circulating progenitor cells are dramatically amplified by stress signals such as injury, bleeding and bacterial or viral infection, presumably contributing to host defense and repair mechanisms. 4 Clinical stem cell mobilization regimens, including repeated daily stimulations with the cytokine granulocyte colony stimulating factor (G-CSF), mimic this process, leading to enhanced proliferation, differentiation and recruitment of stem and progenitor cells to the circulation, allowing their harvest for stem cell transplantation protocols. [5] [6] [7] [8] The chemokine stromal cell derived factor-1 (SDF-1, CXCL12) is a potent chemoattractant for human and murine hematopoietic stem cells. 9 SDF-1 and CXCR4 are highly expressed in human and murine BM endothelium, reticular cells and endosteal osteoblasts. [9] [10] [11] [12] Enhancement of plasma SDF-1 levels using adenoviral vectors, 13 stabilized methionine-SDF-1 (ref. 14) or injection of sulfated polysaccharides, 15, 16 as well as administration of a CXCR4 agonist 17 correlated with induced progenitor cell mobilization. Complementing the established role of the SDF-1/CXCR4 axis in mobilization, the sympathetic nervous system recently emerged as a novel regulator of stem and progenitor cell egress from the BM in steady state, 18 as well as following G-CSF administration, via norepinephrine (NE) signaling, suppression of osteoblast function and downregulation of SDF-1 in the bone. 19 Neurotransmitters together with myeloid cytokines also directly regulate human progenitor cell migration and development, as well as in vivo proliferation and mobilization of murine progenitor cells. 20 In addition, a role for the fibrinolytic system in G-CSF mobilization was recently demonstrated, as G-CSF-induced mobilization resulted in increased levels of chemotactic soluble plasminogen activator receptor (uPAR), 21 whereas addition of plasmin to G-CSF increased mobilization of both murine and human hematopoietic progenitors. 22 G-CSF-induced mobilization also involves Reactive Oxygen Species (ROS) generation in hematopoietic progenitors, correlating with their enhanced egress and motility, involving c-Met signaling. 23 Although G-CSF-induced mobilization is a multi-step process that includes enhanced proliferation and differentiation in the BM, rapid mobilization protocols are characterized by recruitment of stem and progenitor cells from the existing BM reservoir to the circulation within a few hours after a single injection of the mobilizing agent. 8, 24 One such agent is AMD3100 (also termed plerixafor), which inhibits SDF-1-mediated migration in vitro by blocking the chemokine binding to its major receptor CXCR4. 25, 26 AMD3100 has been shown to rapidly mobilize immature progenitor cells from the BM into the blood in murine, 27 non-human primate 28 and humans. 26, 29 It has been recently approved for clinical mobilization in lymphoma and multiple myeloma patients undergoing autologous transplantation. 26 When combined with G-CSF, AMD3100 synergistically augments mobilization of human, primate and murine progenitor cells, which have increased in vitro migration to a gradient of SDF-1 and repopulation of transplanted non-obese diabetic/severe combined immunodeficient mice. 27, [30] [31] [32] However, the mechanisms mediating rapid mobilization of stem and progenitor cells from the BM are poorly understood. As SDF-1/CXCR4 interactions are needed for stem and progenitor cell homing and retention in the BM, it is thought that disruption of these interactions by CXCR4 antagonists, such as AMD3100 or T140, is the cause of accelerated egress to the circulation. 8, 24, [27] [28] [29] Unexpectedly, we have now discovered that AMD3100 has an additional active role in the rapid mobilization of CXCR4 þ immature murine progenitor cells. Both AMD3100-and NE-induced mobilization are dependent on enhanced release of functional SDF-1 to the murine circulation from activated BM stromal cells. Moreover, AMD3100 treatment activates the protease uPA in a CXCR4 and JNK-dependent manner.
Materials and methods
See Supplementary Information in the Leukemia website (http:// www.nature.com/leu) for detailed description of experimental protocols.
Cell culture and reagents
Human BM aspirates were obtained from healthy donors for allogeneic transplantations following informed consent. Human primary BM endothelial cells (BMEC) were isolated from these samples as previously described. 11 The purity of endothelial cells, at first passage, was 91-94% as assessed by expression of von Willebrand's factor (Dako, Glostrup, Denmark), determined by flow cytometry. The human osteosarcoma cell line MG63 were cultured, as described. 10 The following reagents were used: recombinant human SDF-1a (R&D Systems, Minneapolis, MN, USA); AMD3100 (Sigma-Aldrich, Rehovot, Israel or Anormed, Langley, BC, CanadaFsee Supplementary Information); N-Acetyl-L-Cysteine (NAC), NE and ICI (Sigma-Aldrich) and JNK inhibitor (Calbiochem, Darmstadt, Germany). Chemically synthesized SDF-1 and biotinylated SDF-1 3/6 (bSDF-1 3/ 6) were kindly provided by Drs Fujii (Kyoto, Japan) and Baleux (Paris, France), respectively.
Animals and treatment procedures
The Weizmann Institute Animal Care and Use Committee approved all animal experiments. BALB/c and C57BL/6 mice (8-10 weeks) were purchased from Harlan, (Rehovot, Israel). Non-obese diabetic/severe combined immunodeficient mice were bred and maintained as described. 7 Rhesus macaques (Macaca mulatta) were housed and handled in accordance with guidelines set by the Committee of Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council, and the protocol was approved by the Animal Care and Use Committee of the National Heart, Lung and Blood Institute. For functional SDF-1 concentration analyses and cell mobilization studies, mice received either subcutaneous injections of AMD3100 (5 mg/kg in 200 ml phosphate-buffered saline (PBS)), intraperitoneal injections of either NE (5 mg/kg in 400 ml PBS), b2 adrenergic antagonist ICI (5 mg/kg in 400 ml PBS) or intra-femoral injections of bSDF-1 3/6 (5 mg in 5 ml of PBS) to anesthetized mice. Control mice received matched injections of PBS. Where indicated, a total of 50 mg mouse anti-human CXCR4 (12G5, R&D Systems), rabbit antirat-CXCR4 (Torrey Pines Biolabs, East Orange, NJ, USA), anti-SDF-1 (K15C, INRA, Paris, France) or matched control IgG Ab were first injected into the peritoneum (25 mg in PBS) followed by intravenous injection of additional 25 mg Ab, 30 min later, with or without subcutaneously injected AMD3100. A double dose of Ab (2 Â 50 mg) was given to the C57BL/6 strain. Noteworthy, the anti-human CXCR4 Ab (clone 12G5) that was used in our model is cross-reactive to murine CXCR4 (ref. 11) and is also capable of efficiently inhibiting migration of murine BM mononuclear cells towards SDF-1 similarly to the polyclonal rabbit anti-rat CXCR4 Ab (Supplementary Figure S1) . SP600125, JNK inhibitor (30 mg/kg) in 200 ml PPCES vehicle or PPCES alone (control) was administered into the peritoneum 15 min before AMD3100 administration. 33 See Supplementary Information for NAC treatment in vivo. Mice were asphyxiated with CO 2 and peripheral blood samples were collected by cardiac aspiration in heparinized tubes and BM was flushed with PBS. Where indicated, mice were killed exactly 10-60 min post intra-femoral injection and placed on ice, bones were immediately removed and flushed in PBS. After centrifugation, plasma and BM supernatants were collected and used for detection of SDF-1 protein by ELISA and uPA by zymography (See Supplementary Information for details). Cell pellets were used for colony-forming assay or flow cytometry as detailed in Supplementary Information. For the primate studies, blood samples for CBC determination and CD34 þ enumeration were collected 1 h after administration of a single subcutaneous dose of 1 mg/kg AMD3100.
SDF-1 secretion assays
Confluent primary human BMEC and MG-63 cells cultured in 24-well plates, washed twice in pre-warmed PBS and stimulated by either AMD3100, NE or ICI at the indicated concentrations in serum-free media supplemented with 100 mg/ml cycloheximide (Sigma-Aldrich) at 37 1C. After 3 h, the supernatants were collected and analyzed for N-terminally intact SDF-1 content by ELISA.
Statistical analysis
Data were analyzed statistically by analysis of variance. Single factor or P-value was calculated using two-tailed Student's t-test, Excel 2008. Error bars represent s.e.
Results

CXCR4
-dependent release of SDF-1 from BM stromal cells promotes egress and rapid mobilization of hematopoietic progenitor cells
We examined whether or not functional SDF-1 (intact N-terminal) is released to the circulation during steady state, and evaluated its potential effects on egress of immature and mature leukocytes. Mice were injected with neutralizing antibodies (Ab) for SDF-1 or CXCR4. At 1 h after administration, CXCR4 neutralization by Ab markedly decreased the concentration of circulating SDF-1 (Figure 1a) . Interestingly, increased levels of functional SDF-1 were found in the BM (Figure 1a) , suggesting that SDF-1 transport to the circulation is defective, thus it is accumulated in the BM. Although SDF-1-neutralizing Ab did not affect egress of leukocytes to the circulation CXCR4-dependent rapid mobilization of progenitors A Dar et al (Figure 1b ), CXCR4-neutralizing Ab increased their numbers (Figure 1b) . In contrast, the egress of hematopoietic progenitor cells was selectively inhibited by neutralizing monoclonal anti-SDF-1 Ab, and more dramatically by mouse monoclonal anti-CXCR4 Ab (Figure 1b) . Rabbit polyclonal anti-CXCR4 Ab was also capable of inhibiting steady-state egress of progenitor cells (data not shown). Administration of rabbit isotype control Ab did not affect the numbers of circulating cells in steady state (data not shown) and administration of mouse isotype control Ab increased the levels of both mature leukocytes and immature progenitor cells in the circulation (Figure 1b ), most probably due to activation of the murine complement system in a IgGdependent manner as previously described. 34 To rule out nonspecific effects, which could be mediated by activation of the complement system via Ab binding to CXCR4 þ cells in vivo, a complement inhibitor was given to the mice. Administration of anti-CXCR4 Ab to mice pre-treated with a complement system inhibitor resulted in the same reduction of progenitor cell egress as observed with mice, which were not pre-treated (Supplementary Figure S2 ), thus excluding indirect effects of the Ab. To study whether there is a physiological role for SDF-1 release from the BM to the circulation, we tested its levels after AMD3100 treatment, as a model for rapid mobilization in mice 27 and non-human primates. 28 A single injection of AMD3100 resulted in a rapid increase in SDF-1 concentrations in the circulation of mice ( Figure 1c ) and non-human primate (Figure 1e ). Accordingly, decreased SDF-1 levels were documented in the BM of treated mice within 1 h (Figure 1c) . Elevation in circulating SDF-1 concentrations corresponded with rapid mobilization of both mature and immature murine ( Figure 1d ) and non-human primate (Figures 1f and g ) hematopoietic cells. Of note, AMD3100 from two different sources (i.e., Sigma and AnormedFcurrently Genzyme, Cambridge, MA, USA) was compared, demonstrating similar mobilization rates of different types of colony-forming hematopoietic progenitor cells (Supplementary Figures S3a and b) . We have previously demonstrated that BMEC transfer SDF-1 between the blood and the BM via their CXCR4 receptors.
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In accordance and similarly to the effect in steady-state conditions (Figures 1a and b) , co-injection of neutralizing mouse anti-CXCR4 Ab to mice treated with AMD3100 markedly decreased the levels of circulating SDF-1 compared with isotype control Ab-treated mice ( Figure 1c ). Rabbit polyclonal anti-CXCR4 Ab was also capable of inhibiting AMD3100-induced progenitor cell mobilization (data not shown). Although our murine strain model is BALB/c, we have examined also the C57Bl/6 strain, demonstrating that a double dose of anti-CXCR4 Ab is required to inhibit AMD3100- 
CXCR4-dependent rapid mobilization of progenitors A Dar et al
Ab together with AMD3100 inhibited the mobilization of Lin À Sca-1 þ c-Kit þ cells, which are enriched for hematopoietic stem cells (Supplementary Figure S4c) . These results, taken into account together with the accumulation of SDF-1 in the BM, imply that blockage of CXCR4 did not interfere with SDF-1 secretion from BM stromal cells, but impaired CXCR4-dependent translocation of SDF-1 from the BM to the circulation. The inhibition of SDF-1 release was accompanied by a significant reduction in the number of circulating immature colony forming cells, but not mature leukocytes (Figure 1d) . Additionally, SDF-1-neutralizing Ab significantly reduced circulating progenitor cells, compared with AMD3100 alone, with no significant change in total leukocyte counts (Figure 1d) . Noteworthy, independent results in BALB/c mice co-treated with Anormedderived AMD3100 and neutralizing anti-CXCR4 Ab, revealed similar inhibition of AMD3100-induced progenitor cell mobilization, over mature leukocytes ( Supplementary Figures S3c and  d) . Short-term effects of AMD3100 administration on SDF-1 release and mobilization were evaluated 10 min after a single injection of AMD3100. Although the concentrations of SDF-1 in the BM extracellular fluids were significantly increased within 10 min, the levels of circulating SDF-1 were similar to those of PBS-treated mice (Figure 2a) . Mobilization of colony forming cells could not be identified at this early time point (Figure 2b ). Altogether, these results point out that SDF-1 release from the BM to the circulation is a key step in progenitor cell egress and rapid mobilization from the BM. Following a second injection of AMD3100 after an interval of additional hour, the levels of SDF-1, the number of circulating WBCs and colony forming progenitors were not further increased in comparison with those measured 1 h after a single injection of AMD3100 (Figures 2c and  d) . By 24 h after a single injection of AMD3100, the levels of circulating SDF-1 (Figure 2c ) and the number of circulating progenitors (Figure 2d ) did not exceed basal levels compared with control mice. These observations indicate that a single AMD3100 stimulation can induce rapid and substantial release of SDF-1 from the BM to the circulation, which correlates with rapid recruitment of BM-residing progenitor cells to the circulation.
AMD3100 directly induces SDF-1 secretion from CXCR4
þ BM stromal cells
To further demonstrate the ability of the BM to release SDF-1 to the circulation and the associated recruitment of CXCR4 þ progenitor cells, biotin-labeled SDF-1 (bSDF-1) was injected into the murine femur with or without administration of AMD3100. To exclude a potential passive release of SDF-1-binding heparan sulfate 16 to the circulation, we used the bSDF-1 analog, bSDF-1 3/6, which cannot bind heparan sulfate but can still bind and activate CXCR4. 35 The concentrations of the active N-terminally intact form of bSDF-1 3/6 were measured in the plasma and in the extracellular fluids of the injected femur, as well as in non-injected bones, 10, 30 and 60 min after intrafemur injection. bSDF-1 3/6 was detected within the BM fluids of non-injected bones, as early as 10 min post administration (Figure 3a) . In addition, the levels of bSDF-1 3/6 in the BM fluids of the injected femur decreased with time and were significantly lower 60 min post administration (Figure 3a) . Co-injection of AMD3100 (s.c) with bSDF-1 3/6 (intra-bone) resulted in a significant reduction in bSDF-1 3/6 levels in the injected bone, as well as in non-injected bones 60 min after administration (Figure 3a) . In accordance, the concentrations of circulating bSDF-1 3/6 gradually increased up to 60 min following intrafemoral injection, further enhanced by AMD3100 co-administration (s.c) (Figure 3b ). In parallel, we observed a significant increase in the frequency of hematopoietic progenitors in the circulation and their decrease in the BM, 60 min after intra-bone injection of bSDF-1 3/6, further enhanced by AMD3100 coadministration (s.c) (Figure 3c ). The changes in progenitor cell levels correlated with the elevation of circulating bSDF-1 3/6 and reduction of bSDF-1 3/6 concentrations in the BM fluids, suggesting that SDF-1 actively mediates progenitor trafficking. (Figure 3d ). SDF-1 expression was notably reduced in both compartments, 1 h after a single injection of AMD3100 (Figure 3d) . Likewise, only weak immunoreactivity of intracellular SDF-1 was detected in cultured primary human BMEC, which also highly express CXCR4, 11 treated with 100 ng/ml of AMD3100 as compared with untreated cells, which express high levels of intracellular SDF-1 (Figure 3e) . Incubation of CXCR4 þ BMEC, or the CXCR4 þ human osteoblastic cell line MG63 with AMD3100 resulted in increased functional SDF-1 release to the conditioned medium (Figure 3f) . These results are compatible with release of SDF-1 from internal storage compartments of BM stromal cells in response to AMD3100. In addition, circulating mononuclear cells released negligible amounts of SDF-1 in comparison with BM stromal cells, and did not respond to AMD3100 stimulation (Supplementary Figure S5) . Interestingly, AMD3100 at concentrations higher than 500 ng/ ml failed to induce SDF-1 secretion from primary human BMEC or MG63 (Supplementary Figure S6 ). These results demonstrate that SDF-1 is actively secreted from stromal cells rather than released from the cell surface due to competitive binding of AMD3100. Collectively, these observations reveal complex activities of this compound in vivo and suggest that the rapid AMD3100-induced mobilization of hematopoietic progenitor cells involve diverse CXCR4 interactions, SDF-1 secretion and downstream events within the BM compartment affecting CXCR4-expressing hematopoietic and stromal cells.
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ROS signaling is involved in AMD3100-induced mobilization of hematopoietic progenitor cells
Increased ROS levels are associated with HGF and G-CSFinduced mobilization of hematopoietic progenitor cells. 23 Concomitant inhibition of ROS by NAC resulted in a significant reduction in the number of G-CSF-mobilized hematopoietic progenitors. 23 We sought to find out whether ROS signaling also has a role in rapid mobilization to the circulation induced by AMD3100. ROS inhibition by NAC led to a preferential inhibition of AMD3100-induced progenitor mobilization, over mature WBC (Figure 4a ). In addition, NAC inhibited AMD3100-induced SDF-1 release to the circulation, correlating with inhibition of mobilization (Figure 4b ). Of interest, NAC treatment in vivo does not affect the levels of circulating WBC and progenitors in steady state, 23 suggesting generation of ROS in response to AMD3100. Altogether, the involvement of ROS suggests an activation of signaling pathways by AMD3100 in a SDF-1-dependent manner, and further supports the notion of rapid mobilization as an active process rather than a passive inhibitory one.
Adrenergic signals induce rapid SDF-1 release and recruitment of progenitor cells
We tested whether NE, previously implicated in G-CSF-induced mobilization, 19, 20 can induce rapid mobilization by a mechanism similar to AMD3100. We found that a single injection of NE caused a significant increase in circulating SDF-1 within 1 h (Figure 5a ). Concomitantly, we observed an increase in the frequency of circulating progenitors, with no change in the number of circulating mature leukocytes (Figure 5b ). We tested whether inhibition of adrenergic signaling could induce the (Figure 5b ). Neither NE nor ICI altered the numbers of circulating leukocytes when administered alone or when injected with AMD3100 (Figure 5b ). In addition, the concentrations of SDF-1 were elevated in the BM of ICI injected mice in comparison with those measured in the BM of control mice, coinciding with decreased levels of circulating SDF-1 and progenitor cells (Figures 5a and b) . To evaluate a potential role for adrenergic receptors in direct regulation of SDF-1 secretion, the cell surface expression of these receptors on human BMEC was evaluated. Flow cytometry and reverse-transcription PCR analyses revealed that cultured BMEC expressed b2-adrenergic receptors (Figure 5c ). Moreover, these cells responded to ICI by reducing SDF-1 secretion in vitro (Figure 5d ), implying that b2-adrenergic signaling is involved in SDF-1 secretion. As CXCR4 is also expressed by neurons, 37, 38 it is possible that b2-adrenergic signaling may exert an effect downstream to CXCR4. Alternatively, these two pathways may exert an effect independently in the regulation of SDF-1 secretion. To distinguish between these possibilities, we isolated catecholaminergic neurons from superior cervical ganglia (SCG), which express CXCR4 by PCR (data not shown), and tested whether AMD3100 or SDF-1 might alter the uptake or the release of radiolabeled NE in SCG culture explants. As shown in Supplementary Figure S7a , although the re-uptake inhibitor desipramine markedly reduced the uptake of radiolabeld NE, pre-treatment of the explants with AMD3100, with or without SDF-1, did not affect NE uptake by SCG explants. In addition, NE release from SCG explants was not enhanced by AMD3100 or SDF-1 (Supplementary Figure  S7b) . However, KCl-induced NE release was significantly enhanced in the presence of SDF-1 (Supplementary Figure  S7b) , implying a positive feedback loop between SDF-1 and NE release during progenitor cell mobilization. Given the similar effects of AMD3100 and NE administration, we examined whether these signaling pathways cooperate with each other. Chemical sympathectomy by treatment of neonate mice with 6-hydroxybutamine (6OHDA) did not affect the number of progenitors in the BM (data not shown), but it noticeably reduced the number of progenitors elicited in the circulation (Figure 5e ). However, 6OHDA treatment of adult mice, which does not cross the blood-brain barrier, did not affect AMD3100-induced mobilization (Figure 5e ), suggesting that this effect is mediated by the central nervous system.
AMD3100 induces protease activation and progenitor cell mobilization in a CXCR4/JNK signaling-dependent manner
The involvement of the plasminogenic system in G-CSF-induced mobilization was recently reported. 21, 22 SDF-1, CXCR4 and c-jun N-terminal kinase (JNK) signaling were shown to be involved in activation of the serine protease urokinase plasminogen activator (uPA) in a breast cancer invasion model. 39 Considering that AMD3100 induces SDF-1 secretion, we evaluated uPA activity levels in AMD3100-treated mice. Circulating uPA activity was upregulated 1 h post AMD3100 administration (Figures 6a and c) . The AMD3100 amplification effect on uPA activity is CXCR4-dependent as injection of neutralizing CXCR4 Ab together with AMD3100 inhibited the elevation effect (Figure 6a ). This implies that BM-released SDF-1 mediates uPA secretion to promote hematopoietic progenitor cell mobilization in a CXCR4-dependent manner. Comparable to CXCR4 neutralization, injection of a specific JNK inhibitor before AMD3100 administration reduced the activation of uPA (Figure 6c) , as well as mobilization of WBC and progenitor cells (Figure 6b) . Inhibition of JNK signaling in steady-state conditions did not affect the constitutive egress of mature WBC and immature progenitors (Figure 6b ) nor did it affect the constitutive 
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A Dar et al release of SDF-1 to the circulation (Figure 6d ). This suggests that JNK functions as a 'stress kinase' that is recruited upon AMD3100 administration to facilitate cell mobilization. In addition, mice that were pre-treated with JNK inhibitor did not mobilize progenitors in response to AMD3100 injection, and also exhibited a mild but significant reduction in SDF-1 release to the circulation (Figure 6d ). These results suggest that JNK signaling not only regulates protease activation, but is also involved in SDF-1 release to the circulation. Furthermore, a significant reduction in AMD3100-induced uPA activation in the blood circulation was observed following ROS inhibition by NAC (Figure 6e ). Taken together, these data imply that in order to promote progenitor cell mobilization, AMD3100 activates a signaling pathway, involving ROS, to induce SDF-1 secretion, which in turn mediates uPA activation in a CXCR4/JNKdependent manner.
Discussion
It is currently believed that disruption of the interactions between the CXCR4 receptor expressed by hematopoietic progenitors and SDF-1 expressed by BM stromal cells is sufficient to detach anchored progenitors from their BM niches, leading to their rapid mobilization to the peripheral blood. Nevertheless, although neutralizing anti-CXCR4 or anti-SDF-1 antibodies inhibit G-CSF-induced mobilization, 7, 23 steady-state progenitor cell egress and AMD3100-induced mobilization (current study), these antibodies are incapable of inducing progenitor cell mobilization by themselves. Importantly, several reports demonstrate that mobilization of hematopoietic and pro-angiogenic progenitor cells is triggered and maintained by rapid or sustained elevation in the concentrations of circulating SDF-1, or by repeated intra-peritoneum injections of this ligand. 13, 14, 16, 40, 41 On the basis of our findings, we introduce a novel agonistic effect of AMD3100, resulting in enhanced SDF-1 release from BM stromal cells to the circulation that together with its inhibitory effect in vivo (which we think is transient and short-lived) induces rapid mobilization of hematopoietic progenitor cells. CXCR4-dependent SDF-1 transportation to the circulation actively promotes preferential egress of hematopoietic progenitors from the BM during steady-state homeostasis and in the course of rapid mobilization with AMD3100 or catecholamines. However, we cannot rule out involvement of other cell types in this rapid SDF-1 release, such as SDF-1 secretion by activated platelets. 42 Several reports have demonstrated a correlation between elevated SDF-1 levels in the circulation or reduced SDF-1 levels in the BM and the AMD3100-induced mobilization rate of different populations, including hemangiogenic cells, 43 monocytes 44 and hematopoietic progenitors. 45 Of interest, monocytes, sequestered in the BM following CCR2 antagonism, 44 and hematopoietic progenitors, which did not egress to the circulation in wounded diabetic mice, 45 were capable of being mobilized in response to the elevated SDF-1 levels in the circulation following AMD3100 treatment. In addition, repetitive administration of AMD3100 did not enhance the mobilization of hemangiogenic cells 43 or hematopoietic progenitors in another study. 46 These findings support our results and previous observations that a higher dose of AMD3100 results in a slightly weaker capacity to mobilize 27 and Supplementary Figure S2) , and that an additional injection of AMD3100 within 2 h failed to induce another wave of mobilization along with its inability to further elevate SDF-1 levels. Interestingly, conditional deletion or inhibition of sphingosine-1-phosphate receptor-1 (S1P1) resulted in impaired AMD3100-induced mobilization of immature B cells 47 and hematopoietic progenitors. 48, 49 Furthermore, sphingosine-1-phosphate (S1P) treatment was found to modulate SDF-1 secretion. 49 Of interest, the plasma levels of S1P, which serves as a potent chemoattractant for hematopoietic progenitors as well, are increased following AMD3100 administration. 50, 51 Thus, S1P, SDF-1 and probably additional factors may cooperate in the AMD3100-induced preferential mobilization of progenitor cells. In another study, murine hematopoietic progenitor cells that lack fibroblast growth factor receptor 1 (FGFR1) showed impaired SDF-1-induced migration in vitro and AMD3100-induced mobilization in vivo. 52 Altogether, the defects of these different models in responding to AMD3100 suggest an active rather than a passive inhibitory process of AMD3100-induced rapid mobilization. In this study, we found that ROS inhibition by NAC treatment preferentially reduced the numbers of AMD3100-mobilized progenitor cells, correlating with inhibition of SDF-1 release and activation of uPA in the blood circulation. As ROS signaling is associated with G-CSFinduced mobilization and motility and does not affect steady-sate egress, 23 we may further assume that AMD3100 administration induces active signaling. Regarding cell motility, it should be noted that the use of AMD3100 in combination with G-CSF in vivo was shown to increase the responsiveness of mobilized human CD34 þ progenitors to SDF-1 chemotaxis in vitro. 27 These findings suggest that AMD3100 engages additional players in vivo and therefore its effects include more than only a direct antagonism of CXCR4, as previously shown in vitro. This hypothesis surprisingly gains support from another field of research, showing different effects of AMD3100 in vitro and in vivo. AMD3100 is able to block the CXCR4 receptor and to inhibit HIV replication in vitro at nanomolar concentrations. 53, 54 However, it was unable to decrease HIV viral load in HIV-infected individuals. 55 One possible difference is the involvement of BM stromal cells that also functionally express CXCR4. 9 In support of our results, it was recently demonstrated that a layer of BMEC reduces the inhibitory effect of AMD3100 on CXCR4-dependent migration by 10-100 fold, using in vitro trans-endothelial migration assay, wherein CXCR4 þ CXCR7 þ tumor cells were allowed to migrate across BMEC towards SDF-1. 56 We have now shown that blockage of SDF-1 and CXCR4 signaling preferentially inhibits steady-state egress and AMD3100-induced mobilization of progenitors, but not mature leukocytes. We found that administration of NE is accompanied by increased levels of circulating SDF-1 and rapid mobilization, preferentially also of progenitor cells. In agreement with our results, it has recently been shown that circadian modulations in the number of circulating progenitors are mediated by rhythmic synthesis of SDF-1 in the BM, which is regulated by b3-adrenergic receptors. 18 In addition, NE regulates G-CSF-induced mobilization of progenitor cells, affecting both hematopoietic progenitor motility via adrenergic receptors 20 and production of SDF-1 by osteoblasts in the BM. 19 These findings together with our results suggest that the rich and tight association of efferent nerve terminals with BM stromal cells 57 directly impacts on hematopoietic progenitor cell retention and rapid mobilization via modulation of SDF-1 expression and release from BM stromal cells. G-CSF-induced mobilization of human and murine progenitor cells also involves SDF-1 secretion and CXCR4 signaling. 7, 58, 59 Neutralization of CXCR4 strongly reduces G-CSF-induced mobilization of both human and murine progenitor cells. 7 In support of our findings, CXCR4
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À/À hematopoietic cells in CXCR4 þ BM chimeras do not mobilize in response to G-CSF. 60 Furthermore, rapid mobilization of murine progenitor cells using fucoidan, which releases SDF-1 from heparan sulfate complexes, was selectively inhibited with co-administration of neutralizing Ab against SDF-1. 16 Likewise, mobilization by a daily injection of SDF-1, HGF or RANKL for 3-5 days was shown to preferentially recruit murine progenitor cells over mature leukocytes in a SDF-1/CXCR4-dependent manner. 41 Of note, activation of the complement cascade is also needed for optimal AMD3100-induced mobilization. 61 Activation of MMP-9 in response to G-CSF-induced mobilization is well established, 62, 63 and was also documented following AMD3100 administration 61, 64 (and our unpublished data), demonstrating that MMP-9 is also involved in the process of rapid mobilization. Furthermore, the plasminogen system was recently found to participate in murine and human mobilization. 21, 22 Systemic administration of plasminogen activator generates circulating plasmin from plasminogen, which in turn activates MMP-9 in the BM. 65 Altogether, these and our results imply that the enhanced activation and release of MMP-9, in the course of AMD3100-induced mobilization, can be related to the increased release of SDF-1 and uPA to the circulation. In another model, interactions between CXCR4-expressing human breast carcinoma cells and SDF-1-presenting stromal cells were shown to enhance in vitro malignant cell invasion via upregulation of both uPA and uPAR expression, mediated by sustained activation of JNK. 39 We reveal that CXCR4-dependent JNK signaling, initiated by in vivo AMD3100-induced SDF-1 secretion from BM stromal cells, results in activation of uPA, 66 which participates in the release of SDF-1 to the circulation and is crucial for progenitor cell mobilization. Of note, JNK also seems to be involved directly in leukocyte motility, as its inhibition strongly reduces AMD3100-induced mobilization. Importantly, neutralizing CXCR4 Ab, as well as ROS inhibition inhibited AMD3100-induced SDF-1 release and uPA activation. We have previously reported that BM endothelial and other stromal cells actively participate in regulation of SDF-1 availability due to their surface expression of CXCR4, 11 and thus control the homing of human progenitors across the murine blood-bone marrow barrier. In this study, we revealed that inhibition of progenitor cell egress and mobilization can occur because of impairment of CXCR4-dependent translocation of BM SDF-1 across this barrier to the circulation. In summary, we introduce data to support a new concept that CXCR4, which is functionally expressed on BM stromal cells, as well as on hematopoietic progenitor cells, actively participates in preferential regulation of steady-state egress and rapid mobilization of progenitors, via modulation of SDF-1 secretion and release and protease activation. Enhanced CXCR4-dependent release of SDF-1 from BM stromal cells can potentially induce the replacement of former SDF-1/CXCR4 anchoring interactions with directional migratory signals, leading to rapid mobilization of progenitors to the circulation. Our results further underline a direct and active role of CXCR4 signaling, SDF-1 release, proteolytic enzymes and signals from the nervous system in regulation of steady-state egress and rapid mobilization of hematopoietic progenitor cells as part of host defense and repair mechanisms with clinical relevance.
